Download PDF
Semin Liver Dis 2010; 30(1): 003-016
DOI: 10.1055/s-0030-1247128
© Thieme Medical Publishers

Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis

Morris Sherman1
  • 1Department of Medicine, University of Toronto and University Health Network, Toronto, Canada
Further Information

Publication History

Publication Date:
19 February 2010 (online)

    Permissions and Reprints

ABSTRACT

Hepatocellular carcinoma (HCC) is increasing in incidence in many countries, and is the most common cause of death in patients with cirrhosis. With regular surveillance, small early HCC lesions can be identified. An algorithm has been developed that allows for diagnosis of these lesions. Very early HCC lesions have high cure rates with appropriate treatment. If all these factors are in place most HCCs can be cured.

KEYWORDS

Hepatocellular carcinoma - hepatitis B - hepatitis C - surveillance - ultrasonography - α-fetoprotein - desgamma carboxyprothrombin - AFP-L3

REFERENCES

  • 1 Bosch F X, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127(5, Suppl 1) S5-S16
    CrossrefPubMedSearch in Google Scholar
  • 2 Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan.  Cancer Res. 1987;  47(18) 4967-4972
    PubMedSearch in Google Scholar
  • 3 Taylor-Robinson S D, Foster G R, Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94.  Lancet. 1997;  350(9085) 1142-1143
    PubMedSearch in Google Scholar
  • 4 Deuffic S, Poynard T, Buffat L, Valleron A J. Trends in primary liver cancer.  Lancet. 1998;  351(9097) 214-215
    PubMedSearch in Google Scholar
  • 5 Stroffolini T, Andreone P, Andriulli A et al.. Characteristics of hepatocellular carcinoma in Italy.  J Hepatol. 1998;  29(6) 944-952
    CrossrefPubMedSearch in Google Scholar
  • 6 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med. 1999;  340(10) 745-750
    CrossrefPubMedSearch in Google Scholar
  • 7 Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan.  J Gastroenterol. 2009;  44(Suppl 19) 102-107
    CrossrefPubMedSearch in Google Scholar
  • 8 Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.  Hepatology. 2008;  48(1) 137-145
    CrossrefPubMedSearch in Google Scholar
  • 9 King H, Locke F B. Cancer mortality among Chinese in the United States.  J Natl Cancer Inst. 1980;  65(5) 1141-1148
    PubMedSearch in Google Scholar
  • 10 Rosenblatt K A, Weiss N S, Schwartz S M. Liver cancer in Asian migrants to the United States and their descendants.  Cancer Causes Control. 1996;  7(3) 345-350
    CrossrefPubMedSearch in Google Scholar
  • 11 McCredie M, Williams S, Coates M. Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975-1995.  Br J Cancer. 1999;  79(7-8) 1277-1282
    CrossrefPubMedSearch in Google Scholar
  • 12 Beasley R P, Hwang L Y, Lin C C, Chien C S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.  Lancet. 1981;  2(8256) 1129-1133
    PubMedSearch in Google Scholar
  • 13 Sakuma K, Saitoh N, Kasai M et al.. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study.  Hepatology. 1988;  8(6) 1642-1646
    CrossrefPubMedSearch in Google Scholar
  • 14 Fattovich G, Giustina G, Degos F et al.. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.  Gastroenterology. 1997;  112(2) 463-472
    CrossrefPubMedSearch in Google Scholar
  • 15 Bruix J, Barrera J M, Calvet X et al.. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.  Lancet. 1989;  2(8670) 1004-1006
    PubMedSearch in Google Scholar
  • 16 Niederau C, Lange S, Heintges T et al.. Prognosis of chronic hepatitis C: results of a large, prospective cohort study.  Hepatology. 1998;  28(6) 1687-1695
    CrossrefPubMedSearch in Google Scholar
  • 17 Sun C A, Wu D M, Lin C C et al.. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan.  Am J Epidemiol. 2003;  157(8) 674-682
    CrossrefPubMedSearch in Google Scholar
  • 18 Ikeda K, Saitoh S, Koida I et al.. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.  Hepatology. 1993;  18(1) 47-53
    CrossrefPubMedSearch in Google Scholar
  • 19 Benvegnù L, Fattovich G, Noventa F et al.. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study.  Cancer. 1994;  74(9) 2442-2448
    CrossrefPubMedSearch in Google Scholar
  • 20 Cottone M, Turri M, Caltagirone M et al.. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein.  J Hepatol. 1994;  21(6) 1029-1034
    CrossrefPubMedSearch in Google Scholar
  • 21 Borzio M, Bruno S, Roncalli M et al.. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study.  Gastroenterology. 1995;  108(3) 812-817
    CrossrefPubMedSearch in Google Scholar
  • 22 Pateron D, Ganne N, Trinchet J C et al.. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.  J Hepatol. 1994;  20(1) 65-71
    CrossrefPubMedSearch in Google Scholar
  • 23 Colombo M, de Franchis R, Del Ninno E et al.. Hepatocellular carcinoma in Italian patients with cirrhosis.  N Engl J Med. 1991;  325(10) 675-680
    CrossrefPubMedSearch in Google Scholar
  • 24 Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004.  Hepatology. 2008;  48(1) 137-145
    CrossrefPubMedSearch in Google Scholar
  • 25 Fargion S, Fracanzani A L, Piperno A et al.. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis.  Hepatology. 1994;  20(6) 1426-1431
    CrossrefPubMedSearch in Google Scholar
  • 26 Caballería L, Parés A, Castells A, Ginés A, Bru C, Rodés J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis.  Am J Gastroenterol. 2001;  96(4) 1160-1163
    PubMedSearch in Google Scholar
  • 27 Goedert J J. Second Multicenter Hemophilia Cohort Study . Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001–2003.  Haemophilia. 2005;  11(5) 516-528
    CrossrefPubMedSearch in Google Scholar
  • 28 Livraghi T, Meloni F, Di Stasi M et al.. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?.  Hepatology. 2008;  47(1) 82-89
    CrossrefPubMedSearch in Google Scholar
  • 29 Sala M, Llovet J M, Vilana R Barcelona Clínic Liver Cancer Group et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.  Hepatology. 2004;  40(6) 1352-1360
    CrossrefPubMedSearch in Google Scholar
  • 30 Lu S N, Wang J H, Chen P F et al.. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults.  Cancer Epidemiol Biomarkers Prev. 2008;  17(7) 1813-1821
    CrossrefPubMedSearch in Google Scholar
  • 31 Mima S, Sekiya C, Kanagawa H et al.. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan.  J Gastroenterol Hepatol. 1994;  9(4) 361-365
    CrossrefPubMedSearch in Google Scholar
  • 32 Yu E W, Chie W C, Chen T H. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients?.  Cancer J. 2004;  10(5) 317-325
    CrossrefPubMedSearch in Google Scholar
  • 33 Chan A C, Poon R T, Ng K K, Lo C M, Fan S T, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening.  Ann Surg. 2008;  247(4) 666-673
    CrossrefPubMedSearch in Google Scholar
  • 34 Stravitz R T, Heuman D M, Chand N et al.. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.  Am J Med. 2008;  121(2) 119-126
    CrossrefPubMedSearch in Google Scholar
  • 35 Chen J G, Parkin D M, Chen Q G et al.. Screening for liver cancer: results of a randomised controlled trial in Qidong, China.  J Med Screen. 2003;  10(4) 204-209
    CrossrefPubMedSearch in Google Scholar
  • 36 Zhang B H, Yang B H, Tang Z Y. Randomized controlled trial of screening for hepatocellular carcinoma.  J Cancer Res Clin Oncol. 2004;  130(7) 417-422
    PubMedSearch in Google Scholar
  • 37 Sarasin F P, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis.  Am J Med. 1996;  101(4) 422-434
    CrossrefPubMedSearch in Google Scholar
  • 38 Arguedas M R, Chen V K, Eloubeidi M A, Fallon M B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.  Am J Gastroenterol. 2003;  98(3) 679-690
    CrossrefPubMedSearch in Google Scholar
  • 39 Patel D, Terrault N A, Yao F Y, Bass N M, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.  Clin Gastroenterol Hepatol. 2005;  3(1) 75-84
    CrossrefPubMedSearch in Google Scholar
  • 40 Lin O S, Keeffe E B, Sanders G D, Owens D K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.  Aliment Pharmacol Ther. 2004;  19(11) 1159-1172
    CrossrefPubMedSearch in Google Scholar
  • 41 Thompson Coon J, Rogers G, Hewson P et al.. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.  Br J Cancer. 2008;  98(7) 1166-1175
    CrossrefPubMedSearch in Google Scholar
  • 42 Ishizawa T, Hasegawa K, Aoki T et al.. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.  Gastroenterology. 2008;  134(7) 1908-1916
    CrossrefPubMedSearch in Google Scholar
  • 43 Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases . Management of hepatocellular carcinoma.  Hepatology. 2005;  42(5) 1208-1236
    CrossrefPubMedSearch in Google Scholar
  • 44 Chen C J, Yang H I, Su J REVEAL-HBV Study Group et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.  JAMA. 2006;  295(1) 65-73
    CrossrefPubMedSearch in Google Scholar
  • 45 Tong M J, Hsien C, Song J J et al.. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis.  Dig Dis Sci. 2009;  54(6) 1337-1346
    CrossrefPubMedSearch in Google Scholar
  • 46 Chen T H, Chen C J, Yen M F et al.. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.  Int J Cancer. 2002;  98(2) 257-261
    CrossrefPubMedSearch in Google Scholar
  • 47 Chen G, Lin W, Shen F, Iloeje U H, London W T, Evans A A. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.  Am J Gastroenterol. 2006;  101(8) 1797-1803
    CrossrefPubMedSearch in Google Scholar
  • 48 Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years.  Gut. 2008;  57(1) 84-90
    CrossrefPubMedSearch in Google Scholar
  • 49 Sánchez-Tapias J M, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients.  Gastroenterology. 2002;  123(6) 1848-1856
    CrossrefPubMedSearch in Google Scholar
  • 50 Yang H I, Yeh S H, Chen P J REVEAL-HBV Study Group et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.  J Natl Cancer Inst. 2008;  100(16) 1134-1143
    CrossrefPubMedSearch in Google Scholar
  • 51 Yuen M F, Tanaka Y, Fong D Y et al.. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.  J Hepatol. 2009;  50(1) 80-88
    CrossrefPubMedSearch in Google Scholar
  • 52 Chen C J, Yang H I, Iloeje U H et al.. A risk function nomogram for predicting HCC in patients with chronic hepatitis B: The REVEAL.-HBV Study.  J Hepatol. 2007;  46(Suppl 1) S180
    PubMedSearch in Google Scholar
  • 53 Lok A S, Seeff L B, Morgan T R HALT-C Trial Group et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.  Gastroenterology. 2009;  136(1) 138-148
    CrossrefPubMedSearch in Google Scholar
  • 54 Trevisani F, D'Intino P E, Morselli-Labate A M et al.. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.  J Hepatol. 2001;  34(4) 570-575
    CrossrefPubMedSearch in Google Scholar
  • 55 Pateron D, Ganne N, Trinchet J C et al.. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.  , [see comments] J Hepatol. 1994;  20(1) 65-71
    CrossrefPubMedSearch in Google Scholar
  • 56 Marrero J A, Su G L, Wei W et al.. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.  Hepatology. 2003;  37(5) 1114-1121
    CrossrefPubMedSearch in Google Scholar
  • 57 Durazo F A, Blatt L M, Corey W G et al.. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.  J Gastroenterol Hepatol. 2008;  23(10) 1541-1548
    CrossrefPubMedSearch in Google Scholar
  • 58 Sterling R K, Jeffers L, Gordon F et al.. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.  Clin Gastroenterol Hepatol. 2009;  7(1) 104-113
    CrossrefPubMedSearch in Google Scholar
  • 59 Di Bisceglie A M, Hoofnagle J H. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B.  Cancer. 1989;  64(10) 2117-2120
    CrossrefPubMedSearch in Google Scholar
  • 60 Di Bisceglie A M, Sterling R K, Chung R T HALT-C Trial Group et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.  J Hepatol. 2005;  43(3) 434-441
    CrossrefPubMedSearch in Google Scholar
  • 61 Sherman M. Alphafetoprotein: an obituary.  J Hepatol. 2001;  34(4) 603-605
    CrossrefPubMedSearch in Google Scholar
  • 62 Zhou X D, Tang Z Y, Fan J et al.. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma.  J Cancer Res Clin Oncol. 2009;  135(8) 1073-1080
    CrossrefPubMedSearch in Google Scholar
  • 63 Welzel T M, Graubard B I, El-Serag H B et al.. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.  Clin Gastroenterol Hepatol. 2007;  5(10) 1221-1228
    CrossrefPubMedSearch in Google Scholar
  • 64 Fujiyama S, Izuno K, Yamasaki K, Sato T, Taketa K. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves.  Tumour Biol. 1992;  13(5-6) 316-323
    CrossrefPubMedSearch in Google Scholar
  • 65 Okuda H, Nakanishi T, Takatsu K et al.. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.  Cancer. 1999;  85(4) 812-818
    CrossrefPubMedSearch in Google Scholar
  • 66 Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.  J Gastroenterol. 2007;  42(12) 962-968
    CrossrefPubMedSearch in Google Scholar
  • 67 Carr B I, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States.  Dig Dis Sci. 2007;  52(3) 776-782
    CrossrefPubMedSearch in Google Scholar
  • 68 Leerapun A, Suravarapu S V, Bida J P et al.. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.  Clin Gastroenterol Hepatol. 2007;  5(3) 394-402, quiz 267
    CrossrefPubMedSearch in Google Scholar
  • 69 Sterling R K, Jeffers L, Gordon F et al.. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.  Am J Gastroenterol. 2007;  102(10) 2196-2205
    CrossrefPubMedSearch in Google Scholar
  • 70 Capurro M, Wanless I R, Sherman M et al.. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.  Gastroenterology. 2003;  125(1) 89-97
    CrossrefPubMedSearch in Google Scholar
  • 71 Yamauchi N, Watanabe A, Hishinuma M et al.. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.  Mod Pathol. 2005;  18(12) 1591-1598
    PubMedSearch in Google Scholar
  • 72 Marrero J A, Romano P R, Nikolaeva O et al.. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.  J Hepatol. 2005;  43(6) 1007-1012
    CrossrefPubMedSearch in Google Scholar
  • 73 Bolondi L, Sofia S, Siringo S et al.. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.  Gut. 2001;  48(2) 251-259
    CrossrefPubMedSearch in Google Scholar
  • 74 Chen T H, Chen C J, Yen M F et al.. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.  Int J Cancer. 2002;  98(2) 257-261
    CrossrefPubMedSearch in Google Scholar
  • 75 Larcos G, Sorokopud H, Berry G, Farrell G C. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation.  AJR Am J Roentgenol. 1998;  171(2) 433-435
    PubMedSearch in Google Scholar
  • 76 Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer.  J Med Screen. 1999;  6(2) 108-110
    PubMedSearch in Google Scholar
  • 77 Kobayashi K, Sugimoto T, Makino H et al.. Screening methods for early detection of hepatocellular carcinoma.  Hepatology. 1985;  5(6) 1100-1105
    CrossrefPubMedSearch in Google Scholar
  • 78 Takayasu K, Moriyama N, Muramatsu Y et al.. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients.  AJR Am J Roentgenol. 1990;  155(1) 49-54
    PubMedSearch in Google Scholar
  • 79 Miller W J, Baron R L, Dodd III G D, Federle M P. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients.  Radiology. 1994;  193(3) 645-650
    PubMedSearch in Google Scholar
  • 80 Santagostino E, Colombo M, Rivi M Study Group of the Association of Italian Hemophilia Centers et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus.  Blood. 2003;  102(1) 78-82
    CrossrefPubMedSearch in Google Scholar
  • 81 Trevisani F, Cantarini M C, Labate A M Italian Liver Cancer (ITALICA) group et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival.  Am J Gastroenterol. 2004;  99(8) 1470-1476
    CrossrefPubMedSearch in Google Scholar
  • 82 Kim D Y, Han K H, Ahn S H et al.. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual surveillance (Korean experience).  Hepatology. 2007;  46(Suppl 1) 403A
    CrossrefPubMedSearch in Google Scholar
  • 83 Nicolau C, Vilana R, Catalá V et al.. Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions.  AJR Am J Roentgenol. 2006;  186(1) 158-167
    CrossrefPubMedSearch in Google Scholar
  • 84 Iannaccone R, Laghi A, Catalano C et al.. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis.  Radiology. 2005;  234(2) 460-467
    CrossrefPubMedSearch in Google Scholar
  • 85 Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view.  Liver Transpl. 2004;  10(2, Suppl 1) S3-S8
    CrossrefPubMedSearch in Google Scholar
  • 86 Nakashima T, Kojiro M. Hepatocellular Carcinoma. Tokyo; Springer-Verlag 1987
    PubMedSearch in Google Scholar
  • 87 International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia . Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia.  Hepatology. 2009;  49(2) 658-664
    CrossrefPubMedSearch in Google Scholar
  • 88 Libbrecht L, Severi T, Cassiman D et al.. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.  Am J Surg Pathol. 2006;  30(11) 1405-1411
    CrossrefPubMedSearch in Google Scholar
  • 89 Coston W M, Loera S, Lau S K et al.. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.  Am J Surg Pathol. 2008;  32(3) 433-444
    CrossrefPubMedSearch in Google Scholar
  • 90 Park Y N, Kojiro M, Di Tommaso L et al.. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules.  Cancer. 2007;  109(5) 915-923
    CrossrefPubMedSearch in Google Scholar
  • 91 Iwasaki M, Furuse J, Yoshino M, Ryu M, Moriyama N, Mukai K. Sonographic appearances of small hepatic nodules without tumor stain on contrast-enhanced computed tomography and angiography.  J Clin Ultrasound. 1998;  26(6) 303-307
    CrossrefPubMedSearch in Google Scholar
  • 92 Rimola J, Forner A, Reig M et al.. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.  Hepatology. 2009;  50(3) 791-798
    CrossrefPubMedSearch in Google Scholar
  • 93 Forner A, Vilana R, Ayuso C et al.. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.  Hepatology. 2008;  47(1) 97-104
    CrossrefPubMedSearch in Google Scholar
  • 94 Khalili K, Kim T Y, Jang H J, Haider M A, Guindi M, Sherman M. Implementation of AASLD hepatocellular carcinoma practice guidelines in north america:two years of experience.  Hepatology. 2008;  48(Suppl 1) 362A
    PubMedSearch in Google Scholar

Morris ShermanM.B. B.Ch. Ph.D. F.R.C.P.(C.) 

Toronto General Hospital, Room #NCSB 11C 1252

585 University Avenue, Toronto, Ontario, Canada M5G 2N2

Email: morris.sherman@uhn.on.ca